Astrazeneca Pharma India Ltd banner

Astrazeneca Pharma India Ltd
NSE:ASTRAZEN

Watchlist Manager
Astrazeneca Pharma India Ltd Logo
Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
Watchlist
Price: 8 213 INR -1.86% Market Closed
Market Cap: ₹205.3B

Astrazeneca Pharma India Ltd
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Astrazeneca Pharma India Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
Net Issuance of Debt
-₹45.5m
CAGR 3-Years
-6%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Net Issuance of Debt
-₹1.5B
CAGR 3-Years
53%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Net Issuance of Debt
-₹729.7m
CAGR 3-Years
45%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Net Issuance of Debt
₹22.6B
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Lupin Ltd
NSE:LUPIN
Net Issuance of Debt
₹23B
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Net Issuance of Debt
-₹5.3B
CAGR 3-Years
-13%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
No Stocks Found

Astrazeneca Pharma India Ltd
Glance View

Market Cap
205.3B INR
Industry
Pharmaceuticals

AstraZeneca Pharma India Ltd., a pivotal name in the Indian pharmaceutical landscape, is an integral arm of the global biopharmaceutical titan, AstraZeneca PLC headquartered in Cambridge, UK. The company has woven itself into the fabric of healthcare by consistently delivering novel medicines designed to combat a range of illnesses that include oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory ailments. In India, AstraZeneca Pharma has carved out a reputation for not only introducing cutting-edge research and development capabilities but also adapting its global innovations to fit the unique demands of the local market. By leveraging a robust pipeline of therapeutic solutions, the company plays a crucial role in the intersection of healthcare and technology, aiming to improve patient outcomes through personalized medicine and bioscience-led innovations. The business model of AstraZeneca Pharma India is anchored in its commitment to research-driven innovation and strategic partnerships. Revenue streams are tightly interlinked with the company’s ability to successfully commercialize its extensive portfolio of patented medicines. AstraZeneca focuses on maintaining strong relationships with healthcare professionals and stakeholders, which are pivotal in driving prescriptions and ensuring the adoption of its novel therapies. Sales and distribution channels are fortified through collaborations with hospitals, pharmacies, and other healthcare providers, ensuring a broad reach across the country. The company continues to invest in its capabilities to educate and train medical professionals, thus enhancing its influence in the medical community and reinforcing its position as a market leader in providing life-saving medications.

ASTRAZEN Intrinsic Value
3 649.17 INR
Overvaluation 56%
Intrinsic Value
Price ₹8 213

See Also

What is Astrazeneca Pharma India Ltd's Net Issuance of Debt?
Net Issuance of Debt
-45.5m INR

Based on the financial report for Dec 31, 2025, Astrazeneca Pharma India Ltd's Net Issuance of Debt amounts to -45.5m INR.

What is Astrazeneca Pharma India Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
-13%

Over the last year, the Net Issuance of Debt growth was 4%. The average annual Net Issuance of Debt growth rates for Astrazeneca Pharma India Ltd have been -6% over the past three years , -13% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett